tarlatamabDS-7300rovalpituzumabSmall-cell lung cancer (SCLC)SCLC
…metastases and extensive-stage disease. Despite the approval of tarlatamab and ongoing development of DLL3- or B7-H3-targeted ADCs, tumor …
1articles mentioning drugs
1drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: rovalpituzumab ×
rovalpituzumab
This drug is selected. Its supporting articles are shown below.